Will Yabao Help Lupin’s Attempts To Scale The Great Wall?
Executive Summary
With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership
You may also be interested in...
Beijing Rules Against Chugai In China’s First Patent Linkage Suit
A new ruling in China indicates patent holders may have a harder time challenging generic manufacturers.
Younger Females' Cancer Incidence Increases Significantly In China
Latest data show a worrying public health trend that remains the top health concern in China despite surging COVID infections.
Lupin’s Foncoo Partnership Beginning Of China Challenge To AZ, Cipla?
Lupin’s partnership with Shenzhen Foncoo marks the Indian firm's much-awaited entry into China. Will this and more planned alliances make Lupin a worthy respiratory challenger to AstraZeneca, compatriot Cipla and others in a country where chronic respiratory diseases are the second leading cause of death?